Does TISAGENLECLEUCEL Cause Second primary malignancy? 146 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 146 reports of Second primary malignancy have been filed in association with TISAGENLECLEUCEL (KYMRIAH). This represents 3.5% of all adverse event reports for TISAGENLECLEUCEL.
146
Reports of Second primary malignancy with TISAGENLECLEUCEL
3.5%
of all TISAGENLECLEUCEL reports
60
Deaths
37
Hospitalizations
How Dangerous Is Second primary malignancy From TISAGENLECLEUCEL?
Of the 146 reports, 60 (41.1%) resulted in death, 37 (25.3%) required hospitalization, and 20 (13.7%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TISAGENLECLEUCEL. However, 146 reports have been filed with the FAERS database.
What Other Side Effects Does TISAGENLECLEUCEL Cause?
Cytokine release syndrome (1,660)
Pyrexia (1,030)
Malignant neoplasm progression (582)
Hypotension (425)
Immune effector cell-associated neurotoxicity syndrome (416)
Neurotoxicity (411)
Platelet count decreased (397)
White blood cell count decreased (392)
Hypogammaglobulinaemia (374)
Lymphocyte count decreased (365)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which TISAGENLECLEUCEL Alternatives Have Lower Second primary malignancy Risk?
TISAGENLECLEUCEL vs TISLELIZUMAB
TISAGENLECLEUCEL vs TISOTUMAB VEDOTIN
TISAGENLECLEUCEL vs TISOTUMAB VEDOTIN-TFTV
TISAGENLECLEUCEL vs TITANIUM DIOXIDE\ZINC
TISAGENLECLEUCEL vs TIVICAY